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genous psychoses with organic states, and 
since there indeed were some similarities, 
one was left with the impression that the 
endogenous psychoses too were organic in 
nature. Kleist (Kraepelin, 1921) also made 
a reference to Atypical Psychoses—to which 
he assigned the label marginal psychosis. 
In subsequent years the contributions 
of Kraepelin, Vernicke and Kleist either 
lay dormant or were inadequately high-
lighted. It was left to Leonhard (Leonhard, 
1957-1969) to revive the interest with 
vigour, leading to enunciation of an im-
pressive system of classification. Four basic 
types were introduced : 
(i) Affective Psychosis; 
(ii) Cycloid Psychosis; 
(iii) Non-systematic Schizophrenia; 
(iv) Systematic Schizophrenia. 
Affective psychoses were further sub-
divided into— 
(a) Bipolar type 
(b) Monopolar type 
Cycloid Psychoses were similarly cate-
gorized into Anxiety Blissfulness type, con-
fusion type and motility type. 
Non-systematic schizophrenias received 
the sub-categorization into affect-laden para-
phrenia, cataphasia and Periodic catatonia. 
And the systematic schizophrenia included 
hebephrenic, paranoid and catatonic a; 
sub-types. In his system Leonhard viewed 
cycloid psychosis and non-systematic schizo-
phrenia as atypical psychoses. It is thi;s 
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Classifications in psychiatry have 
always posed a challenge, particularly for 
those involved in the pursuit of academic 
systematization of syndromes (Spitzer et 
al., 1978). References are available which 
indicate that Greek Physicians developed 
a system which may well be termed as Bio-
logical (Nancy & Spitzer, 1979). And then 
we have the humoral theorists who advo-
cated the concept of imbalances in the 
humours leading to the imbalance of tem-
paraments (Fisher, 1936). This particular 
concept has not stood the test of time but 
has indeed encouraged a number of workers 
in the past and in recent times towards 
evolving a more acceptable and universal 
frame of reference. 
We are aware of the fact that Kraepelin 
attempted to identify and describe definite 
clinical syndromes (Kraepelin, 1896). In 
particular he arranged mental disorders 
into organic psychosis, endogenous psycho-
sis (without known structural pathology) 
and the deviations of personality and Re-
action states. It may be recalled that endo-
genous psychosis was divided into two ca-
tegories on the basis of phenomenological 
studies, i.e. Dementia Praecox and Manic 
Depressive Insanity. Such a division made 
a tremendous impact, atleast at that time 
when confusion was the prevalent mood in 
terms cf understanding as related to classi-
fication. We would also recall that Kleist 
(Kraepelin, 1921) compared the endo-198  B. B. SETHI it al. 
abundantly clear that Leonhard's concepts 
are quite contrary to what is being followed 
at the present time. 
Not only that, even more surprising is 
that the term endogenous psychosis does 
not appear in the latest edition of the well 
known Comprehensive Text Book of Psy-
chiatry edited by Kaplan et al. (1980). 
It is a pity that the widely' prevalent group 
of mental disorders—schizophrenias—still re-
mains an ill-defined diagnostic category. 
The diagnostic criteria for Schizophrenias 
are as inconsistent as they are diverse 
(Fentor. et al., 1981). In an attempt to 
evolve stringent nosological guidelines, the 
American Psychiatric Association, ended 
up with the emergence of a set of criteria 
(A. P. A., 1980), which has aroused a great 
deal of controversy. The applicability of 
the diagnostic criteria as derived thtough 
the prestigious International Pilot Study 
of Schizophrenia (IPSS) (W.H.O., 1973) 
of the World Health Organization is yet to 
be tested. The controversy evidently ema-
nates from the monistic approach to schizo-
phrenia which is in sharp contrast to the 
pleuristic concept of schizophrenia as ori-
ginally envisioned by Eugene Blculer (1950). 
It is gratifying to observe that the pleu-
ristic conceptualization of schizophrenias has, 
however, been preserved and promoted by 
Karl Leonhard (1979). As pointed out 
above, Leonhard identifies as many as 25 
subtypes of schizophrenias which are 
divisible into two broad types—systematic 
and non-systematic schizophrenias. Among 
others, the recent pharmacotherapeutic find-
ings (Kclwala et al., unpublished study) 
tend to justify the dichotomy—systematic 
and non-systematic—as proposed by Leon-
hard. It is unfortunate that Leonhard's 
comprehensive classification is relatively un-
known outside Europe. 
An added fact relating to various olassi-
ficatory systems point:, out that specific 
types of psychoses are observed in almost 
every culture, particularly, in India (Sethi, 
1978), and yet find no place in the pre-
valent systems of classification. For example 
a type of psychosis frequently associated with 
the abuse of cannabis (Bhang) has been 
identified in India (Verma, 1972 ; Thacore, 
1973 ; Chopra and Smith, 1974). While 
the clinical picture of cannabis psychosis 
shares many a symptoms of paranoid schizo-
phrenia, the two types of psychoses are 
quite di-tinct from each ether (Thacore and 
Shukla, 1974). 
Briefly one may note that cannabis 
use in India is quite common. Prolonged, 
perpetual or even an occasional use of 
cannabis may produce psychiatric illness 
of intense proportions. There is a vast 
literature on the subject, especially from 
countries like India, Egypt, Morocco and 
Nigeria (Baselqu, 1972). Some workers 
contend that cannabis in itself does not have 
the capacity to produce psychiatric illness, 
though it might precipitate such an illness 
in those who are predisposed. In contrast 
some workers (Varma, 1972 ; Thacore 
1973 ; Chopra & Smith, 1974) have de-
scribed conditions known as 'Cannabis 
Psychosis' or 'Bhang Psychosis'. However 
the existence of the entity remains contro-
versial. However, the description of the 
syndrome is considered as being far from 
clear—especially when it is taken into ac-
count that symptoms said to be charac-
teristic of the state are also common to 
other toxic state?, including those associa-
ted with malnutrition and infections. In 
early studies (Kolansky and Moore, 1971 ; 
Halikas et al., 1971)—no specific asso-
ciation between cannabis and psychosis 
was noted. However, (1974) and 
(Agarwal et al. (1975) revived the 
concept and described cases with 
features such as—temporal asso-
ciation with cannabis intake, bizzare or 
aggressive behaviour, elation with increased 
flow of tlv light but no schizophrenic thought 
disorder. It is characterised by complete 
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tiated from paranoid schizophrenias. 
A general consensus seems to be that 
cannabis might precipitate a state of psy-
chosis particularly in those who find it 
difficult to manage anxiety. And possibly 
because of this controversy cannabis psy-
chosis is not listed in ICD-9. 
The term Hysterical Psychosis (Wig 
and Narang, 1969) though in use for a 
long time is also not a part of ICD-9 or-
DSM-III. In the latter it is listed under 
Brief Reactive Psychosis. The main clinical 
feature* are a recognizable stressful event 
preceding appearance of symptoms, emo-
tional turmoil characterized by incoherence, 
markedly illogical talks, delusions, hallu-
cinations, markedly bizzarre behaviour and 
volatile affect. It may last from a few 
hours to a few days. The patients have a 
poor insight. By definition the main pre-
cipitating factor is a major stress experience, 
closely related in time to emergence of 
symptoms. Unstable personalities seem to 
be much prone to develop hysterical psy-
chosis. There are till date no genet
;c links 
demonstrable but the disorder is not con-
sidered as one of the spectrum disorders 
of schizophrenia (Rosenthal and Kety, 
1978). 
In the Bleulerian sense of schizophrenias, 
as also shared, in particular, by Leonhard 
(1979), both, cannabis and hysterical psy-
choses may be conceptualized as only two 
of the myriad forms of schizophrenias. It 
might therefore, seem unwise to label these 
and other related forms of psychoses as 
atypical psychotic disorders, a classification 
which is followed just because of custom 
and convenience. The concept that the 
schizophrenias represent a syndrome with 
different underlying pathological process is 
substantiated by the recent biochemical 
findings which tend to differentiate one 
from the another subtype of schizophrenias 
(Wyett et al., 1980:. 
The bordeiline states form probably 
the most controversial nosological entity. 
After comparing diagnostic criteria, as pro-
posed by Knight (1953), Kernberg 
(1967), Grinker et al. (1968), Gunderson 
and Singer (1975) and Perry and Klerman 
(1978) were obliged to consider the border-
line concept as an illusion. While the 
borderline patients continue to be identified 
(Kroll et al., 1982) the very concept of this 
disorder is undergoing radical revisions. 
Recently, Stone (1979) has traced the con-
temporary shift of the borderline concept 
from a sub-schizophrenic disorder to a 
subaffective disorder. It cannot be over-
emphasized that the borderline states have 
not only defied the definition but also proved 
to be a therapeutic challenge. Therefore, 
this area of research deserves particular 
attention. 
Perhaps because of a strong psycho-
analytical and psychodynamic trends /forces, 
the organic aetiology as conceived by 
Kraepelin (1896), Wernicke, Kleist, 
and Leonhard (1957, 1969) did not 
receive an appropriately justifiable 
attention. And compatible with 
the syndromal and pleuristic view of schizo-
phrenias will be the reasoning that there 
may be more than one etiological basis of 
the development of schizophrenias. A va-
riety of etiological theories including an 
autoimmune theory (Solomon, 1981) of 
schizophrenias have been proposed. I 
should like to comment at length on this 
model, which appears to be based on some 
interesting observations. 
The roles of thymus, T-lymphocytes 
and immunoglobulins in the regulation cf 
immune function remain undisputed. There 
is some evidence that the patients of schizo-
phrenia (Fessel and Hirata-Hibi, 1963 ; 
Fowle, 1968) and their family members 
(Sethi et al., 1973) show morphologic ab-
normalities in lymphocytes. 
In a study conducted in 1971 in our 
department (Sethi et al., 1973) a relationship 
was studied between prescr.ee of atypical 
lymphocytes and psychiatric disorders. It 200  B. B. SETHI et at. 
was pointed out that all schizophrenics 
studied in the series demonstrated atypical 
cells. A much lesser frequency of these 
a typicalities was also observed in depressive 
and psychophysiological disorder
1-'. A sub-
sequent ftudy (Sethi and Sethi, 1971) was 
completed in 1973. A genetic influence 
producing a specific cellular response to 
stress which in schizophrenic patients as-
sumes a different variety as compared to 
conttols and other psychiatric syndromes was 
considered as a possibility. 
Recently, certain functional changes in 
lymphocytes of untreated schizophrenic 
patients have been demonstrated (Var-
tanian et al., 1978). The latter findings are 
extremely important since similar changes 
have also been shown to be caused by pheno-
thiazines (Boker et al., 1977). The question 
of ncuroleptic-induced atypical lympho-
cytes was specifically addressed in a very 
recent investigation which indicated that 
the neuroleptics did not seem to influence 
the occurrence of atypical lymphocytes 
(Hirata-Hibi et al., 1982). The whole area 
of research pertaining to the morphological 
and functional changes in the lymphocytes 
of patients with schizophrenia is so exciting 
that it certainly deserves further explora-
tions, as also emphasized by Solomon (1981). 
The repercussions of the lymphocytic 
abnormalities may be observed in the 
quantitative and qualitative variations of 
serum proteins, particularly immunoglo-
bulins. There are large number of reports 
on changes in the level of y-globulins and 
their fractions in patients with schizophrenia 
(Torrey et al., 1978 ; Prakash and Sethi, 
1978). 
In a study (Tewari, 1981) carried out 
in our department and currently in press 
it was decided to study the pattern of immu-
noglobulins and viral antibodies in serum 
and CSF of schizophrenics and depressive 
subjects, and to determine relationship 
between duration and episode of illness and 
immunoglobulin level and antibody litre. 
The results of the study revealed that 
in depressives (33.6%) and neurological 
controls (45%) total CSF protein was in-
creased while there was no increase in 
schizophrenic patients. High mean serum 
values of Ig G were observed in depressives 
and neurological controls as compared to 
surgical controls, and mean servim value of 
IgA was higher in schizophrenics, depres-
sives and neurological controls as compared 
to surgical controls. Mean value of CSF 
IgG/ total protein % (T.P.) was high in 
schizophrenics, depressives and neurological 
patients as compared to surgical controls. 
CSF IgA was detected in depressives and 
neurological controls but not in schizo-
phrenic and surgical patients. The findings 
of antibrain antibodies and HLA antigens 
specific to schizophrenias (Baron et al., 
1977 ; Pandey et al., 1981) are compatible 
with the autoimmune theory of schizo-
phrenias but are inconclusive. 
The identification of endorphins 
(Hughes et al., 1975) endogenous morphino-
mimetic substances and their implications 
in psychotic disorders forms perhaps the most 
significant research of the past decade. 
A gross inconsistency of the data is equally 
true about the research in this area. The 
controversy is evidenced by the findings 
which suggest an excess of endorphins 
(Terenius et al., 1976 ; Lindstrom et al., 
1978 ; Limon et al., 1980), a deficiency of 
endorphins (Kline et al., 1977 ; Lehman 
et al., 1979) and a poor availability of a 
particular fraction (Y-type) of endorphins 
in patients with schizophrenias (Verhoeven 
et al., 1979 ; 1978 ; Van Praag et al., 1982). 
The literature has been recently reviewed 
by Van Ree et al., (1981). The original 
and perhaps the most popular view excess 
of endorphine has been questioned lately 
on the basis of clinical trials (Gunne et 
al., 1977 ; Davis et al., 1977 ; Janowsky 
et al., 1977 ; Kurland et al., 1977 ; Emrich 
et al., 1978 ; Watson et al., 1978), using an 
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discussed elsewhere. However, it is worth 
noting that due to differential affinity of 
the opiate receptors, antagonists such as 
naloxone may not be the appropriate agents 
for delineating various central roles of 
enkephalins (Mackay, 1979). Because the 
morphinomirnetic substances have been re-
cently found to interact with the dopamin-
ergic system (Van and Wolterink, 1981) 
and because beta endorphins are converted 
into 7 endorphins (Burbach et al., 1980) fur-
ther investigations must be undertaken to 
gain insights into the etiological roles of )8 
and y endorphins in schizophrenia. Such 
investigations are further justified by the 
encouraging therapeutic results with beta 
endorphins and Des-Tyr
1)- Y endorphin 
(Vehoeven et al., 1978 ; 1979 ; Van Praag 
et al, 1982). 
Aetiology therefore of disorders to be 
included in the Endogenous Psychosis group 
remains an enigma of no small magnitude. 
A number of crucial leads are now avail-
able, any of which may be holding the key 
for the future. Genetic, Biochemical, the 
psychodynamic and the social aspects have 
been emphasized from time to time. Of 
late, however only the genetic and the 
Biological theories are receiving the long 
awaited attention. It is worth noting 
that as a result of genetic studies of affective 
disorders presented a system of diagnosis 
in unipolar depression. Winokur and 
Clayton (1969) coined the two sub-
categories : (i) depression spectrum disease 
in which a first degree relative has alcohol-
ism or antisocial personality or both and 
(ii) pure depressive disease in which a 
first degree relative have history of depres-
sion. These nosological categories which 
though do not find a place in standard 
official American Psychiatric Association or 
WHO classification, have been supported 
by distinct genetic, phenomenological and 
outcome features. Their exact nature will 
be clear only in the years to come and with 
more studies (Winokur and Tanna, 1969). 
Leonhard (1957—1969) also described 
atypical schizophrenias which he called 
non-synematic schizophrenias and differ-
entiated from systemic schizophrenias 
(typical) on the basis of phenomenological 
studies and later he proved their independent 
existence on the basis of genetic studies 
in which he found that the rate of genetic 
transmission i.
c much higher and prognosis 
poorer. Though these atypical entities 
of typical endogenous psychosis have recently 
created interest in other workers too, it 
still remains a poorly studied one (Fish, 
1964). 
Currently high risk longitudinal studies 
are in progress in vulnerable subjects. On 
the basis of expectancy rates in genetic 
family studies, the children of one schizo-
phrenic parent (with 10-15% risk) and of 
two schizophrenic parents (with a 40% 
risk), are being studied from early years 
and researchers hope to identify preexisting 
biochemical, psychophysiological, neuro-
logical, behavioural and environmental cha-
racteristics that might differentiate those 
who become schizophrenic from those who 
do not (Van Parag, 1981). A similar 
strategy is also required for affective 
psychosis to solve the genetic riddle, where 
again prospective studies would be more 
valuable. 
Treatment 
Undoubtedly, the neuroleptics remain 
the drugs of choice in the treatment of 
schizophrenia. However, various reasons, 
including the recent identification of a 
syndrome (Gardos and Cole, 1980; of tardive 
dyskinesia in patients receiving neuroleptics 
have promoted the exploration of alternative 
therapeutic agents. We shoild like to 
briefly review the therapeutic results with 
lithium, opiate-antagonists as well as endor-
phins and beta-adrenergic blocking drugs. 
Lithium 
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only reported a lack of therapeutic response 
with lithium in schizophrenics but also a 
development of neurotoxicity (Shopsin et 
al, 1971). While encouraging results had 
been obtained with lithium in individual 
cases of schizophrenia, the research received 
a fresh impetus after the publication of a 
study in 1975 (Small et al, 1975). The 
investigators boldly employed a combi-
nation of lithium and neuroleptics with 
success in spite of the fact that a similar 
therapeutic strategy had been found to 
induce neurotoxicity (Cohen and Cohen, 
1974). A score of investigations have since 
been undertaken with variable success 
(Alexander et al, 1979; Biederman et al, 
1979; Growe et al, 1979). The antiscbi-
zophrenic potential was also explored in a 
double-blind investigation at our center 
(Dube and Sethi, 1981). A total of 60 
inpatients carrying a diagnosis of schizo-
phrenia received lithium or chlorpromazine. 
The 4-week period of active medication was 
preceeded and followed by placebo therapy. 
While, generally speaking, chlorpromazine 
was superior to lithium, the latter produced 
beneficial effects on several core symptoms-
emotional withdrawal, conceptual disorgani-
zation, suspiciousness, ideas of persecution 
and passivity and nonspecific symptoms of 
schizophrenia—somatic concern, motor 
retardation, impaired concentration, excite-
ment, hostility and anxiety. There was no 
evidence of predisposition for neurotoxicity 
in patients receiving lithium. 
In another unpublished study (Dube, 
1980) an evaluation of the antischizophrenic 
effects of lithium-neuroleptic combination 
in 24 patients who had shown only minimal 
response with neuroleptics was completed. 
The patients were classified according to 
Leonhard's criteria. The investigators con-
cluded that lithium-neuroleptic combination 
was effective in unsystematic schizophrenias 
and not only ineffective in systematic 
schizophrenias but also neurotoxic. While 
these findings await replication in controlled 
investigations, they do indicate a therapeutic 
role of lithium in disorders characterised 
by a phasic course as the latter has been 
described as a cardinal feature of unsyste-
matic schizophrenias. The inference is 
lent support by investigations which have 
reported favourable results with lithium in 
schizo-affective disorders (Alexander et al, 
1979; Biederman et al, 1979) also charac-
terised by a phasic course. Our positive 
data together with those reported in the 
literature would caution against the pre-
mature labelling of lithium as exclusively 
antimanic agent. 
Our present understanding of neuro-
anatomy, ncuro physiology neurototrnas-
mitters, neurohormones and psychoneuro-
pharrnacology have opened up new channels 
in the field of endogenous psychoses. The 
mono-amine hypothesis of schizophrenia im-
plicating neurotransmitter dopamine (Carl-
sson and Lindquist, 1963), - Monoamine 
oxidase (Murphy and Wyatt, 197?) and 
aberrant o-methylation of catecholamines 
(Osmond and Smythres, 1952; Domino and 
Gahagan, 1977; Wyatt et al, 1973) and 
GABA (Roberts, 1972) involvement has 
been on one hand supported and on other 
hand refuted, leaving the whole situation 
in a dilemma. More recentlv endorphins 
(Sethi and Prakash, 1981) have been im-
plicated in schizophrenia. This particular 
hypothesis is being tested by the WHO in 
an International Collaborative Study by 
using Naloxone as an opiate antagonist 
(Verhoeven et al, 1981). Another recent 
development is the role of Beta adrenorccep-
ter antagonist propranolol (Schulz et al, 
1980) in schizophrenia. These recent 
developments have undoubtedly made a 
significant advancement in the treatment of 
schizophrenia but the nature of illness still 
remains unresolved, though considerable 
understanding has emerged. 
Opiate Antagonists and Endorphins 
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of opiate antagonists and endorphins in the 
treatment of schizophrenia has been discussed 
elsewhere. The theory that schizophrenias 
are characterised by an excess of endorphins 
has been clinically tested in a score of positive 
(Gunne et al, 1977; Emrich et al, 1978; 
Watson et al, 1978) and negative (Volavka 
et al, 1979; Kvirland et al, 1977) studies. 
It was tested in a prestigious multicenter 
investigation sponsored by the World 
Health Organization. The investigation 
included patients with schizophrenia and 
mania. The results are now available (Sethi 
and Prakash, 1981). At our centre in a 
study of 11 patients with schizophrenias 
who subcutaneously received 0.3 mg/Kg 
of naloxone or placebo, we did not observe 
any significant change in the psychopathology 
upto 6 hours after the medication (Ver-
hoeven et al, 1981). 
The theory of deficiency of endorphins 
is related to the observations of therapeutic 
success with administration of Beta endor-
phin (Kline et al, 1977; Lehman et al, 
1979). It is likely that Beta endorphin-
induced improvement in schizophrenia is 
related to an inherent neuroleptic potential 
because Beta endorphin (Schulz et al, 1980) 
as also other neuroleptics (Meltzer and Fang, 
1976) have been found to elevate prolactin 
levels. The notion is in fact supported by 
the observation that Beta endorphins are 
converted, in brain, into (Des-Tyr
1) 
r-endorphin which is considered to be the 
endogenous neuroleptic and that he adminis-. 
tration of the latter has elicited a favourable 
therapeutic response in schizophrenics (Ver-
hoeven et al, 1978; 1979; Van Praag et al, 
1982). 
And since the results of WHO Colla-
borative study of Naloxone in Manic and 
Schizophrenic patients (Phase-I) indicated 
that there is a range of response to acute 
naloxone administration and that schizo-
phrenic patients concurrently treated with 
neuroleptic medications in particular res-
pond favourably, a phase-II study has been 
initiated with a purpose of examining the 
stability and possible clinical significance of 
the therapeutic effects ofnaloxone in schizo-
phrenic patients using repeated naloxone and 
placebo administration. In this study 
schizophrenic patients who are free on 
neuroleptic medication for past 14 days or 
are on stabilized dose of neuroleptics for at 
least 14 days are being asked to participate. 
The design of the study includes random 
assignment of four consecutive days of place-
bo and fur consecutive days of naloxone. 
Naloxone is being administered subcuta-
neously in a dose of 0.3 mg/kg. b. wt. and 
placebo in a matched volume in identical 
vehicle. Each patient participates in a 
total of 8 days of study. A number of 
variables have been blamed for the incon-
sistency of data in studies with opiate-
antagonists (Emrich et al, 1978; Verebey 
et al, 1978) but since the phase II study 
has been launched by the WHO, it may be 
premature to disregard the etiological and 
or therapeutic roles (s) of endorphins in 
schizophrenia. 
Beta Adrenoceptor Blocking Drugs 
The identification of antipsychotic 
potential of beta adrenoceptor blocking 
drugs was quite a seredipitious discovery 
(Atsmon and Blum, 1970). A score of 
positive (Atsmon et al, 1972; Yorkston et al, 
1974; 1981; 1977; Sheppard, 1979) and 
negative (Gardos et al, 1973; King et al, 
1980; Peet et al, 1981) studies have since 
been reported. An inconsistency of data 
has been attributed to various factors— 
differences in research designs, selection of 
diagnostically heterogenous group of patients, 
differences in the dose of drug, and conjoint 
medication with neuroleptics and beta 
blockers (Prakash and Se'.hi, unpublished 
data ). The last factor has assumed parti-
cular importance due to recent revelations 
of pharmacokinetic interactions between 
the two classes of drugs (Pelt et al, 1981). 
Propranolol has been found to cause ele-204  B. B. SETHI et at. 
vation of plasma levels of neuroleptics, 
thereby reducing the dose requirement of 
the latter. The foregoing interactions and 
effects, if maintained over a period of time 
may minimize the risk of the development 
of tardive dyskinesia. 
It may be of interest to note that we 
took schizophrenic inpatients (Sethi and 
Dube, 1981) who fulfilled the standard 
inclusion and exclusion criteria and ad-
ministered propranolol after a complete 
assessment of physical status. The drug was 
given for 4 weeks according to the following 
regimen : 
Day 1— 6 .. .. 160 mg/day 
Day 7— 9 .. .. 480 mg/day 
Day 10—12 .. .. 960 mg/day 
Day 13—16 .. .. 160,0 mg/day 
Day 17—28 .. .. 1920 mg/day 
Patients whose pulse rate fell below 
55/mt and b.p. below 80/50mm of Hg. 
were dropped from the study. Weekly 
ratings of total scores of MBPRS recorded 
highly significant (pZO.OOl) improvements 
in scores of weeks 2 and 4 when compared 
to the baseline and among themselves similar 
level of improvement was seen on the CPRS 
scores of weeks 2, 3 and 4 when compared to 
the baseline scores and those of week 1. 
The improvement beyond week 3 was 
significant at 1% level only (Mann Whitney-
U-test). Using the students test, 8 items 
of MBPRS showed a highly significant 
improvement (PZO.OOl) at the end of 2 
weeks and maintained till the end of the 
study. On the CPRS subscale, 13 out of 
39 items showed an improvement at 5% 
level after 2 weeks of active treatment. 
During the 3rd and 4 weeks highly significant 
improvements (pZO.Ol) were seen on the 7 
items. Only 3 patients were dropped due 
to severe CVS effects. Most side effects 
when severe occurred during the first 72 
hours of therapy and Beta blocking effects 
were not related to clinical improvement. 
Our observation is that the drug possesses 
antipsychotic properties and is safe. Double 
blind studies are recommended for further 
exploring this lead. 
CONCLUSIONS AND RECOMMENDATIONS 
1. Schizophrenias represent a hetero-
genous group of disorders. With few excep-
tions, the available classificatory systems 
do not seek to minutely and clearly discern 
various subtvpes of schizophrenias. Certain 
culture-related forms of psychoses have 
to be classified as atypical disorders for want 
of specific diagnostic categories. Also, the 
issue of borderline psychoses remains un-
resolved. The nosological problems appear 
to be related to exclusion of pleuristic 
approach to schizophrenias, asoriginally 
envisioned by Eugene Bleuler. Further 
expansion of the available diagnostic systems, 
along the lines of Leonhard, must be done. 
2. A heterogenous group of disorders 
cannot be conceived to have just one etiologi-
cal basis and one therapeutic answer. The 
theories linking immunological changes and 
changes in the endorphin systems with 
schizophrenias are two of the various 
etiological models of schizophrenias. Mor-
phological and functional patterns in lym-
phocytes of patients with schizophrenias 
appear to be immensely significant and need 
further explorations. 
In the area of endorphin research, 
further investigations with beta-endorphins 
and (Des-Tyr
1)-endorphin must be under-
taken in patients with schizophrenias. 
Lithium and beta adrenoceptor-blocking 
drugs constitute a good treatment in addition 
to neuroleptics, if not alone in their own 
right. There is, however, some need for the 
identification of individual subtypes of 
schizophrenias which lespond to different 
therapeutic strategies. A multi-centre study 
of atypical psychoses with particular atten-
tion to genetic, neuro humoral, psycho-
pharmacological and pharmacological aspects 
should be of help in clarifying a variety of 
ismes raised. 
Lastly we wish to emphasize thatBiologi-THEORETICAL ISSUES OF ENDOGENOUS PSYCHOSES  205 
cal Psychiatry now provides an excellent 
scientific base of knowledge, methodology 
and clinical applicability. But more is 
required to be studied in order to clarify 
several issues involved in endogenous 
psychoses. A major research work is being 
done in advanced countries—especially the 
affluent ones. In developing countries there 
is paucity of research work and information. 
Two major factors hampering research work 
ate : (a) lack of facilities for research train-
ing and (b) lack of facilities and resources 
for research (Sethi, 1980). The problem 
in setting up biological research for endo-
genous psychoses in India would arise from 
various sources. Lack of manpower, finan-
cial unavailability, lack of well equipped 
laboratories, limited familiarity with research 
methods and inadequate transfer of infor-
mation are the outstanding problems prone 
to affect research work. Malnutrition, 
illiteracy cultural beliefs and lack of spon-
sorship may be other factors likely to affect 
research work (Sethi and Sharma, 1981). 
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